Medazepam

Jump to: navigation, search
Medazepam
Medazepam skeletal.png
Medazepam3d.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  •  ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life36-150 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H15ClN2
Molar mass270.8
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Medazepam

Articles

Most recent articles on Medazepam

Most cited articles on Medazepam

Review articles on Medazepam

Articles on Medazepam in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Medazepam

Images of Medazepam

Photos of Medazepam

Podcasts & MP3s on Medazepam

Videos on Medazepam

Evidence Based Medicine

Cochrane Collaboration on Medazepam

Bandolier on Medazepam

TRIP on Medazepam

Clinical Trials

Ongoing Trials on Medazepam at Clinical Trials.gov

Trial results on Medazepam

Clinical Trials on Medazepam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Medazepam

NICE Guidance on Medazepam

NHS PRODIGY Guidance

FDA on Medazepam

CDC on Medazepam

Books

Books on Medazepam

News

Medazepam in the news

Be alerted to news on Medazepam

News trends on Medazepam

Commentary

Blogs on Medazepam

Definitions

Definitions of Medazepam

Patient Resources / Community

Patient resources on Medazepam

Discussion groups on Medazepam

Patient Handouts on Medazepam

Directions to Hospitals Treating Medazepam

Risk calculators and risk factors for Medazepam

Healthcare Provider Resources

Symptoms of Medazepam

Causes & Risk Factors for Medazepam

Diagnostic studies for Medazepam

Treatment of Medazepam

Continuing Medical Education (CME)

CME Programs on Medazepam

International

Medazepam en Espanol

Medazepam en Francais

Business

Medazepam in the Marketplace

Patents on Medazepam

Experimental / Informatics

List of terms related to Medazepam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medazepam is a drug that is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and skeletal muscle relaxant properties. It is known by the following brand names: Azepamid, Nobrium, Tranquirax (mixed with Bevonium), Rudotel, Raporan, Ansilan and Mezapam.[1] Medazepam is a long-acting benzodiazepine drug. The half-life of medazepam is 36 – 200 hours.[2]

Pharmacology

Benzodiazepine drugs including medazepam increase the inhibitory processes in the cerebral cortex by allosteric modulation of the GABA receptor.[3] Benzodiazepines may also act via micromolar benzodiazepine-binding sites as Ca2+ channel blockers and significantly inhibited depolarization-sensitive calcium uptake in experiments with cell components from rat brains. This has been conjectured as a mechanism for high dose effects against seizures in a study.[4] It has major active benzodiazepine metabolites, which gives it a more prolonged therapeutic effects after administration.[5]

Chemistry

Medazepam can be synthesized in various ways. One is via the reduction of the carbonyl group in diazepam (lacking methyl in Ex 1) by lithium aluminium hydride. N.B. If diazepam is reduced with LAH as in Ex 9, actually the product produced is 7-chloro-1-methyl-5-phenyl-1,2,4,5-tetrahydro-3H-1,4-benzodiazepine, not medazepam.

Medazepam synthesis 1:[6] E. Reeder, Nutley, L.H. Sternbach, Template:US Patent (1963).

A second way of making medazepam consists of the initial reduction of the carbonyl group by lithium aluminum hydride into 7-chloro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one—the first intermediate product in the synthesis of diazepam—which is synthesized by the cyclocondensation of 2-amino-5-chlorobenzophenone with glycine ethyl ester into 7-chloro-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepine, and the subsequent methylation of the secondary amine nitrogen atom of the resulting product by methyl iodide, using sodium hydride as a base.

Medazepam synthesis 2: S. Inaba, H. Nagata, DE 1934385  (1971). G.A. Archer, E. Fells, L.H. Sternbach, Template:US Patent (1964).

A third method of making medazepam consists of a new way of making 7-chloro-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepine, which consists in heterocyclization of 1-(2,5-dichlorophenyl)-1-phenylimine with ethylenediamine. The starting 1-(2,5-dichlorophenyl)-1-phenylimine is synthesized by the reaction of 2,5-dichlorobenzonitrile with phenylmagnesium bromide.

Medazepam synthesis 3: S. Inaba, H.Nagata, DE 1934385  (1969).

A fourth method of making medazepam from 4-chloro-N-methylaniline is suggested. The last is reacted with aziridine (or ethylene imine) in the presence of aluminum chloride, giving N-(4-chlorophenyl)-N-methylethylenediamine.[7] Acylation of the resulting product with BzCl gives the respective amide, which cyclizes into the desired medazepam using phosphorus oxychloride.

Medazepam synthesis 4: K.H. Heinrich, DE 1695188  (1967) DE 1795811  (1967).

A fifth method also exists:

Medazepam synthesis 5[8]


See also

References

  1. Encyclopedia of Drugs: Benzodiazepines
  2. Professor heather Ashton (April 2007). "BENZODIAZEPINE EQUIVALENCY TABLE". Retrieved September 23, 2007.
  3. Zakusov VV; Ostrovskaya RU; Kozhechkin SN; Markovich VV; Molodavkin GM; Voronina TA. (October 1977). "Further evidence for GABA-ergic mechanisms in the action of benzodiazepines". Archives internationales de pharmacodynamie et de thérapie. 229 (2): 313–26. PMID 23084.
  4. Taft WC; DeLorenzo RJ (May 1984). "Micromolar-affinity benzodiazepine receptors regulate voltage-sensitive calcium channels in nerve terminal preparations" (PDF). Proc Natl Acad Sci USA (PDF). 81 (10): 3118–22. doi:10.1073/pnas.81.10.3118. PMC 345232. PMID 6328498.
  5. Jochemsen R, Breimer DD (1984). "Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles". Curr Med Res Opin. 8 Suppl 4: 60–79. doi:10.1185/03007998409109545. PMID 6144464.
  6. Template:Cite doi
  7. GB 1153103 
  8. Template:Cite doi

External links


Linked-in.jpg